By Christopher P. Singer --
Nventa Biopharmaceuticals Corporation announced on October 29, 2007 that U.S. Patent 7,262,014, titled "Immune responses against HPV antigens elicited by compositions comprising an HPV antigen and a stress protein or an expression vector capable of expression of these proteins" has been granted by the U.S. Patent and Trademark Office. The '014 patent relates to compositions and methods for inducing or enhancing immune response to human papillomavirus (HPV) with or without adjuvant. According Nventa's press release, the patent provides a method for treating a tumor expressing HPV antigen by administering an effective amount of a composition of an HPV antigen fused to a stress protein, and additionally provides exclusivity for HspE7, an investigational therapeutic vaccine.
The '014 patent issued from U.S. Application No. 10/938,695 (filed September 10, 2004) and claims priority through a number of divisional and continuation applications as well as to a provisional application, filed on August 5, 1997. The patent contains a total of 15 claims relating to methods of treatment. Representative independent Claims 1 and 3 recite:
1. A method of treating a tumor exhibiting an HPV protein antigen, the method comprising administering to a subject having the tumor an effective amount of an expression vector that encodes and is capable of directing expression of a fusion protein comprising the HPV protein antigen fused to a stress protein.
3. A method of treating a tumor expressing an HPV protein antigen, the method comprising administering to a subject an effective amount of a composition comprising the HPV protein antigen joined to a stress protein.
Comments